Small molecules with antiviral activity against the Ebola virus

F1000Research

Volumn 4, Issue , 2015, Pages

  Ekins, Sean ^a,c   Litterman, Nadia ^a   Lipinski, Christopher ^b  

^a Collaborative Drug Discovery ^*  (United States)

^b Christopher A Lipinski PhD LLC   (United States)

^c Collaborations in Chemistry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMODIAQUINE; ANTIVIRUS AGENT; BCX 4430; BRINCIDOFOVIR; C 7950925; CHLOROQUINE; CLOMIFENE; COMPOUND 7910528; DRONEDARONE; FAVIPIRAVIR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TOREMIFENE; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIVIRAL ACTIVITY; DRUG ACTIVITY; DRUG DATABASE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL CHEMISTRY; MOLECULAR WEIGHT; NONHUMAN; PHARMACOPHORE; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

EID: 84924943796     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.6120.1     Document Type: Review

References (37)

1. Martinez JP Sasse F Brönstrup M: Antiviral drug discovery: broad-spectrum drugs from nature. Nat Prod Rep. 2015;32(1):29-48. 25315648 10.1039/c4np00085d
2. Anon. World Health Organization media center.2014. Reference Source
3. Debing YD Jochmans J Neyts J: Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol. 2013;3(2):217-24. 23562753 10.1016/j.coviro.2013.03.001
4. Simmons CP Wolbers M Nguyen MN: Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl Trop Dis. 2012;6(9):e1752. 23029567 10.1371/journal.pntd.0001752 3459884
5. Stadler K Masignani V Eickmann M: SARS--beginning to understand a new virus. Nat Rev Microbiol. 2003;1(3):209-18. 15035025 10.1038/nrmicro775
6. Raj VS Osterhaus AD Fouchier RA: MERS: emergence of a novel human coronavirus. Curr Opin Virol. 2014;5:58-62. 24584035 10.1016/j.coviro.2014.01.010 4028407
7. De Clercq E: Strategies in the design of antiviral drugs. Nat Rev Drug Discov. 2002;1(1):13-25. 12119605 10.1038/nrd703
8. De Clercq E: Antivirals and antiviral strategies. Nat Rev Microbiol. 2004;2(9):704-20. 15372081 10.1038/nrmicro975
9. De Clercq E: Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol. 2015;93(1):1-10. 25481298 10.1016/j.bcp.2014.11.008
10. Brown CS Lee MS Leung DW: In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol. 2014;426(10):2045-58. 24495995 10.1016/j.jmb.2014.01.010 4163021
11. Han Z Lu J Liu Y: Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. J Virol. 2014;88(13):7294-306. 24741084 10.1128/JVI.00591-14 4054416
12. Opsenica I Burnett JC Gussio R: A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. J Med Chem. 2011;54(5):1157-69. 21265542 10.1021/jm100938u 3056319
13. Johnson JC Martinez O Honko AN: Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res. 2014;107:102-9. 24815087 10.1016/j.antiviral.2014.04.014 4103912
14. Johansen LM Brannan JM Delos SE: FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013;5(190):190ra79. 23785035 10.1126/scitranslmed.3005471 3955358
15. Madrid PB Chopra S Manger ID: A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013;8(4):e60579. 23577127 10.1371/journal.pone.0060579 3618516
16. Gehring G Rohrmann K Atenchong N: The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69(8):2123-31. 24710028 10.1093/jac/dku091
17. Ekins S Freundlich JS Coffee M: A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000Res. 2014;3(277). 10.12688/f1000research.5741.1
18. Kazmi, F Hensley T Pope C: Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013;41(4):897-905. 23378628 10.1124/dmd.112.050054 3608459
19. Nadanaciva S Lu S Gebhard DF: A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro. 2011;25(3):715-23. 21184822 10.1016/j.tiv.2010.12.010
20. Oestereich L Lüdtke A Wurr S: Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17-21. 24583123 10.1016/j.antiviral.2014.02.014
21. Anon. French nurse cured of Ebola contracted in Liberia.2014. Reference Source
22. Florescu DF Keck MA: Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti Infect Ther. 2014;12(10):1171-8. 25120093 10.1586/14787210.2014.948847
23. Anon. Chimerix's Brincidofovir Has in Vitro Activity Against Ebola.2014. Reference Source
24. Bishop BM: Potential and Emerging Treatment Options for Ebola Virus Disease. Ann Pharmacother. 2015;49(2):196-206. 25414384 10.1177/1060028014561227
25. Warren TK Wells J Panchal RG: Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402-5. 24590073 10.1038/nature13027
26. Litterman N Lipinski CA Bunin BA: Computational Prediction and Validation of an Expert's Evaluation of Chemical Probes. J Chem Inf Model. 2014;54(10):2996-3004. 25244007 10.1021/ci500445u
27. Lipinski CA Litterman NK Southan C: Parallel Worlds of Public or Commercial Bioactive Chemistry Data. J Med Chem. 2014; In Press. 25415348 10.1021/jm5011308
28. Baell JB Holloway GA: New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J Med Chem. 2010;53(7):2719-2740. 20131845 10.1021/jm901137j
29. Baell J Walters MA: Chemistry: Chemical con artists foil drug discovery. Nature. 2014;513(7519):481-3. 25254460 10.1038/513481a
30. Clark AM Williams AJ Ekins S: Cheminformatics workflows using mobile apps. Chem-Bio Informatics J. 2013;13:1-18. Reference Source
31. Wolf MC Freiberg AN Zhang T: A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 2010;107(7):3157-62. 20133606 10.1073/pnas.0909587107 2840368
32. Hohman M Gregory K Chibale K: Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today. 2009;14(5-6):261-70. 19231313 10.1016/j.drudis.2008.11.015
33. Ekins S Freundlich JS Hobrath JV: Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. Pharm Res. 2014;31(2):414-35. 24132686 10.1007/s11095-013-1172-7 3946937
34. Ekins S Reynolds RC Kim H: Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery. Chem Biol. 2013;20(3):370-378. 23521795 10.1016/j.chembiol.2013.01.011 3607962
35. Veljkovic V Loiseau PM Figadere B: Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Res. 2015;4:34. 10.12688/f1000research.6110.1
36. Kouznetsova J Sun W Martínez-Romero C: Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerging Microbes Infect. 2014;3:e84. 10.1038/emi.2014.88
37. Long J Wright E Molesti E: Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res. 2015;4:30. Reference Source